Medindia

X

Bionovo to Present at the Southern California Investor Conference

Thursday, August 12, 2010 Press Release J E 4
Advertisement


EMERYVILLE, Calif., Aug. 12 Bionovo, Inc. (Nasdaq: BNVI), a drug discovery and development company focused on the unmet needs in women's health and oncology, today announced that Tom Chesterman, Senior Vice President and Chief Financial Officer, will be presenting at the Southern California Investor Conference at 11:00 a.m. PT on Tuesday, August 17, 2010. The event will be held at the Island Hotel in Newport Beach, California.

Interested parties can access a live audio webcast of the presentation by visiting http://bionovo.com/investors/events or at http://events.powerstream.net/002/00581/20100817_SCIC_BioNovo/. A replay of this webcast will also be available for up to one year following the conference at http://bionovo.com/investors/events.

About Bionovo, Inc.

Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The Company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

SOURCE Bionovo, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Halozyme Announces Issuance of U.S. Patent for rHu...
S
Vermillion Reports Financial Results for the Secon...